Back to search results

Understanding Cancer Cachexia in Pancreatic Cancer

This observational study is looking at how genetic differences (genomic polymorphisms) might be connected to cancer cachexia (CC) in people with pancreatic adenocarcinoma (PDAC). Cancer cachexia is a serious problem for many pancreatic cancer patients, causing muscle and fat loss that can't be fixed by regular nutrition. Researchers want to understand why some people develop CC by looking at their genes and other health information. The study will involve 100 participants aged 18 and older. The main goal is to see if certain genetic markers are linked to CC, which will be measured around 3 months into the study. This information could help doctors better understand and potentially treat CC in the future.

Study design
This is an observational study involving 100 participants. It is not testing a new treatment, but rather observing factors that may contribute to cancer cachexia.
What's involved
You would provide written informed consent and HIPAA authorization. Specimens, such as blood or buccal swabs, may be collected during a standard clinic visit.
Compensation
Not stated in the trial record.
Follow-up
Cancer cachexia will be measured at approximately 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05376592

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

Recruiting
Not specifiedAges 18+Observational
Wake Forest University Health Sciences
~100 participants
Updated 2026-07-23 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cancer cachexia (CC)
Measured over approx. 3 months

Conditions

Pancreas Adenocarcinoma
Cachexia

Explore related trials

Pancreatic Adenocarcinoma

NCT05376592

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolinastudy coordinator listed

    Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kunal Kadakia, MD · PRINCIPAL_INVESTIGATOR · Atrium Health Levine Cancer Institute

Who to contact

CynDavia McKoy
[email protected]
704-355-2000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent and HIPAA authorization for release of personal health information by the subject in accordance with the practices of the Levine Cancer Institute and Atrium Health. NOTE: HIPAA authorization will be included in the informed consent.
Male or female patients age ≥ 18 years at the time of consent
Histological or cytological confirmation of pancreatic adenocarcinoma, with a diagnosis of locally advanced unresectable PDAC (LAPC) or metastatic pancreatic adenocarcinoma. LAPC is defined as per NCCN 16. Note: Subject can be enrolled at any time during their cancer course following histologic diagnosis.
Able to provide a blood or buccal sample.

Exclusion

None

What this trial measures

  • Cancer cachexia (CC)approx. 3 months

    A binary variable will be determined for each subject indicating if they have developed CC within 3 months after diagnosis as defined as weight loss of at least 5%.